Potential 307% Upside Draws Investor Interest
For investors seeking high-risk, high-reward opportunities, Gossamer Bio, Inc. (NASDAQ: GOSS) presents a compelling case in the biotechnology sector. This clinical-stage biopharmaceutical company, headquartered in San Diego, California, is currently focused on advancing treatments for pulmonary arterial hypertension (PAH), a serious cardiovascular condition. Gossamer Bio’s lead candidate, seralutinib (GB002), is garnering significant attention due to its progression into Phase 3 clinical trials and potential to address unmet medical needs in the PAH treatment landscape.
Currently trading at $2.21, Gossamer Bio’s stock remains within a 52-week range of $0.67 to $3.46. The stock’s recent price movement is relatively stable,…
